Aethlon Medical Demonstrates Ability to Capture Colorectal and Lymphoma Cancer Exosomes

Dec 20, 2010, 06:30 ET from Aethlon Medical, Inc.

SAN DIEGO, Dec. 20, 2010 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

In the lymphoma study, conducted at the City of Hope Cancer Research Hospital in California, exosomes derived from lymphoma patients were circulated through Aethlon Medical's Hemopurifier®.  Each sample confirmed significant exosome capture rate validating that the company's Hemopurifier® is a candidate therapy to address lymphoma.  

In a separate study, exosomes derived from colorectal cancer patients were also circulated through the company's Hemopurifier®.  The results for the colorectal study also confirmed significant exosome capture rate and the prospect of applying the Hemopurifier® as a therapeutic for this type of cancer.  The company anticipates providing additional details of these studies in a forthcoming report.

Additionally, as previously announced, Exosome Sciences, Inc., a wholly owned subsidiary of Aethlon Medical, is developing its proprietary ELLSA assay that will allow researchers to detect exosomes in blood and other fluids.  These studies further validate the company's detection assay in identifying lymphoma and colorectal cancer derived from cancer-released exosomes. As a result, this diagnostic tool offers the potential to improve lymphoma and colorectal cancer diagnosis and monitor disease progression.

The Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. Lymphoma is a cancer in the lymphatic of the immune system and presents as a liquid tumor of lymphoid cells. According to the Leukemia & Lymphoma Society, an estimated 21,530 persons will die of lymphoma in the United States in 2010

Colorectal cancer, also called colon cancer or large bowel cancer, includes cancerous growths in the colon, rectum and appendix. With 655,000 deaths worldwide per year, it is the fourth most common form of cancer in the United States and the third leading cause of cancer-related death in the Western world.  

"Our goal is to provide oncologists with an adjunct therapeutic device that will improve treatment of lymphoma and colorectal cancer without adding drug toxicity or interaction risks," stated , Jim Joyce, Aethlon Medical's Chairman and CEO.  "The data also provides supporting evidence that our Hemopurifier® has broad-spectrum applications against various forms of cancer." Aethlon previously demonstrated that its Hemopurifier® successfully captured exosomes derived from ovarian, breast and melanoma cancer patients during in vitro studies.

Aethlon believes the Hemopurifier® represents the sole therapeutic strategy to directly inhibit or reverse the deleterious effects associated with exosomes secreted by tumors as a survival mechanism for cancer. Tumor-secreted exosomes have been reported to trigger programmed cell death (apoptosis) of immune cells; interrupt T-cell signaling required to mount an immune response; inhibit the production of anti-cancer cytokines, and have implications in the spread of metastasis and allowing for angiogenesis.

About Aethlon Medical

At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

  1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
  2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
  3. Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
  4. Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Contacts:

James A. Joyce

Chairman, CEO

858.459.7800 x301

jj@aethlonmedical.com

John P. Salvador

Director, Communications & Investor Relations

858.459.7800 x307

jps@aethlonmedical.com

Jon Cunningham

RedChip Companies, Inc.

800.733.2447 x107

jon@redchip.com

SOURCE Aethlon Medical, Inc.



RELATED LINKS

http://www.aethlonmedical.com